Reviewing Scienture (NASDAQ:SCNX) & Silo Pharma (NASDAQ:SILO)

Silo Pharma (NASDAQ:SILO) and Scienture (NASDAQ:SCNX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Silo Pharma and Scienture, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silo Pharma	1	0	0	0	1.00
Scienture	1	0	1	0	2.00

Scienture has a consensus price target of $1.50, indicating a potential upside of 920.41%. Given Scienture’s stronger consensus rating and higher possible upside, analysts plainly believe Scienture is more favorable than Silo Pharma.

Profitability

This table compares Silo Pharma and Scienture’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Silo Pharma	-6,726.39%	-81.75%	-66.35%
Scienture	N/A	-53.51%	-42.47%

Institutional and Insider Ownership

5.6% of Silo Pharma shares are owned by institutional investors. Comparatively, 5.7% of Scienture shares are owned by institutional investors. 3.6% of Silo Pharma shares are owned by company insiders. Comparatively, 19.5% of Scienture shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

Silo Pharma has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Scienture has a beta of 3.35, suggesting that its stock price is 235% more volatile than the S&P 500.

Earnings and Valuation

This table compares Silo Pharma and Scienture”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silo Pharma	$70,000.00	34.19	-$4.23 million	($4.36)	-0.35
Scienture	$430,000.00	14.04	-$41.51 million	($2.10)	-0.07

Silo Pharma has higher earnings, but lower revenue than Scienture. Silo Pharma is trading at a lower price-to-earnings ratio than Scienture, indicating that it is currently the more affordable of the two stocks.

Summary

Scienture beats Silo Pharma on 12 of the 14 factors compared between the two stocks.

About Silo Pharma

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations and drug delivery systems. The company’s lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. It is also developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company’s two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer’s disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company’s research and development programs are conducted through collaborations with Columbia University and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

About Scienture

Scienture Holdings, Inc. engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.